Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lundbeck obtains European rights to Myriad’s Flurizan
Myriad and Lundbeck have entered into a European commercialization agreement under which Lundbeck will have rights to market and sell Flurizan in the EU and several associated non-EU
Myriad and Lundbeck have entered into a European commercialization agreement under which Lundbeck will have rights to market and sell Flurizan in the EU and several associated non-EU
This is the company’s fifth approval in the US after earlier approvals for Carboplatin, Paclitaxel, Epirubicin & Irinotecan. Mitoxantrone is an antineoplastic agent used in combination with corticosteroids
Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical
Dr Cohen joins Kosan from GE Healthcare Medical Diagnostics where she served as the global oncology therapeutic area head, responsible for strategic development, clinical trial implementation and registration
In a preclinical study, benign prostatic hyperplasia (BPH) was induced through subcutaneous injection of testosterone propionate. One week prior to initiation of testosterone, either D-3263 or finasteride, a
The sNDA submission is based on results of a multi-center, randomized, double-blind study in 699 adult patients, which demonstrated less procedural pain associated with blood draws or IV
The IRB approved study was registered with the National Institute of Health (NIH) and operated under the guidelines of both the NIH and the Israeli Ministry of Health.
The study results show that – 80% of percutaneous tibial nerve stimulation (PTNS) patients considered themselves cured or improved, while 55% of tolterodine LA patients considered themselves cured
The Phase I, open label, dose-escalation trial was designed to evaluate intravesical (into the bladder) administration of CG0070 in patients with superficial bladder cancer who had failed previous
The orphan medicinal product designation provides Phytopharm with market exclusivity in the EU for 10 years following Myogane’s market authorization. In addition to the 10 year market exclusivity,